Praxis Precision Medicines, Inc.
Praxis Precision Medicines (Nasdaq: PRAX) is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders associated with imbalances in neuronal excitation and inhibition. It applies genetic insights from epilepsy to potential treatments for epilepsy and movement disorders,… From the company’s description.
In fiscal 2025, Praxis Precision Medicines, Inc. reported revenue of $0.00M, down 100.0% from fiscal 2024, and a net loss of $303.27M. Operations used $249.07M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Praxis Precision Medicines, Inc. does
In the company’s own words
Praxis Precision Medicines (Nasdaq: PRAX) is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders associated with imbalances in neuronal excitation and inhibition. It applies genetic insights from epilepsy to potential treatments for epilepsy and movement disorders, using two proprietary discovery platforms: Cerebrum™, for small-molecule medicines, and Solidus™, for antisense oligonucleotides. Its clinical-stage candidates include ulixacaltamide for essential tremor, relutrigine for developmental and epileptic encephalopathies, vormatrigine for focal-onset seizures and generalized epilepsy, and elsunersen for SCN2A-related epilepsy. Ulixacaltamide and relutrigine are small molecules, while vormatrigine is an oral small molecule and elsunersen is an antisense oligonucleotide. The Solidus platform also includes preclinical programs targeting PCDH19, SYNGAP1 and SCN2A. The company’s development portfolio spans rare genetic epilepsies, common epilepsies and movement disorders; it reports its business through its research and development activities rather than separate reportable segments. Its website is https://praxismedicines.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1689548
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Praxis Precision Medicines, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Praxis Precision Medicines, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Praxis Precision Medicines, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Praxis Precision Medicines, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Praxis Precision Medicines, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Praxis Precision Medicines, Inc.'s last four quarterly filings that the numbers alone won't show?”